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Abstract
Dinucleoside polyphosphates act as agonists on purinergic P2Y receptors to mediate a variety of cellular processes.
Symmetrical, naturally occurring purine dinucleotides are found in most living cells and their actions are generally
known. Unsymmetrical purine dinucleotides and all pyrimidine containing dinucleotides, however, are not as common
and therefore their actions are not well understood. To carry out a thorough examination of the activities and specificities
of these dinucleotides, a robust method of synthesis was developed to allow manipulation of either nucleoside of the
dinucleotide as well as the phosphate chain lengths. Adenosine containing dinucleotides exhibit some level of activity on
P2Y1 while uridine containing dinucleotides have some level of agonist response on P2Y2 and P2Y6. The length of the
linking phosphate chain determines a different specificity; diphosphates are most accurately mimicked by dinucleoside
triphosphates and triphosphates most resemble dinucleoside tetraphosphates. The pharmacological activities and relative
metabolic stabilities of these dinucleotides are reported with their potential therapeutic applications being discussed.
Abbreviations: araC – arabinocytidine; CDI–carbonyldiimidazole; DCC – dicylohexylcarbodiimide; ppi – inorganic
pyrophosphate; 4-thioU–4-thiouridine
Introduction
Dinucleoside polyphosphates (NPnN0), or dinucleotides, are
important extracellular signalling molecules containing a
polyphosphate backbone capped at each end with a nucleo-
side. Several dinucleoside polyphosphates have been identi-
fied as naturally occurring compounds. They were initially
isolated and characterized from Artemia [1], were later found
in chromaffin cell and platelet granules, and now have been
determined to be ubiquitous in prokaryotic and eukaryotic
cells [2Y4]. Dinucleotides are known with varying phosphate
chain lengths, usually between two and eight phosphate
groups. The most common dinucleotides studied both
biologically and synthetically are the diadenosine polyphos-
phates (APnA), especially where n =3 Y5. These diadenosine
polyphosphates have been proposed to mediate a variety of
functions including inhibition of adenosine kinase and
adenylate kinase [5], stimulation of nitric oxide release from
endothelial cells [6], inhibition of platelet aggregation [7], and
facilitating neurotransmitter release from synaptic terminals
in the central nervous system [8]. Recently, APnAs were
isolated from tear fluid, underscoring their importance in
physiological processes [9, 10]. Interest in the biological
activity of dinucleotides rose with the discovery of the P2
nucleotide receptor family that consists of ligand-gated ion
channels (P2X) and G protein coupled receptors (P2Y).
Dinucleotides have varying activities at these receptors; in
some cases for example, the phosphate chain length of a
diadenosine polyphosphate can dictate agonist or antagonist
activities at the same receptor.
Several dinucleotides have been administered in human
clinical trials. AP4A for example, has been given via i.v.
injection for lowering blood pressure during anesthesia [11].
Successful phase 3 trials using UP4U (diquafosol tetrasodium)
as a treatment for dry eye disease [12, 32] has resulted in an
approvable New Drug Application with the US FDA. A next-
generation dinucleotide (UP4dC, INS37217, denufosol tetra-
sodium) is currently being tested in patients with cystic
fibrosis and retinal detachment [13, 14].
Small quantities of dinucleotides have been available via
enzymatic synthesis, however these methods are largely
limited to purine bases and are not suited for gram scale
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nucleoside bases [1, 15Y19]. Chemical procedures have
also been reported for synthesis of standard and stabilized
dinucleotides [20Y22]. Other syntheses of dinucleotide-like
structures have been developed for inosine 50-monophos-
phate dehydrogenase (IMPDH) inhibitors [23Y25]. Al-
though the purine dinucleotides are more widely known
and available commercially, the pyrimidine analogs where
one or both bases are uridine, cytidine or thymidine, have
not been systematically studied for biological activity
[26Y28]. The full range of purine and pyrimidine dinucleo-
tides holds a great deal of interest to researchers in the field
of purinergic receptors. The increased stability of these
molecules, as well as the potential to manipulate selectivity
based upon choice of nucleobases, can aid in the elucidation
of cellular mechanisms. Hence, methods for the convenient
synthesis of these dinucleotides were needed.
Results and discussion
A variety of coupling protocols to prepare dinucleotides
from their corresponding nucleotides were developed. In
general, these procedures rely on converting the water
soluble salts of nucleotides into organic soluble trialkyl-
ammonium salts, which allows the phosphate couplings to
be carried out under anhydrous conditions in DMF or
DMSO. The illustrated method starts with the conversion
of uridine monophosphate (UMP, 1), uridine diphosphate
(UDP, 3) or UTP (7) from their sodium salts into their
tributylammonium salts followed by activation with either
CDI or DCC in DMF. The activated intermediates were not
isolated, but were directly condensed with another nucleotide
(also as the tributylamine salt) to make symmetrical or mixed
dinucleotides with two, three, or four bridging phosphates
(Figures 1Y3, Tables 1Y3).
Compound1 was treated with CDI to give the phosphori-
midazolide 2 as the activated species [29], and this was
reacted with either 1 or 3 to give diuridine 50-diphosphate
(UP2U, 4) or diuridine 50-triphosphate (UP3U, 5), respec-
tively.
Diuridine 50-tetraphosphate (9) was synthesized by acti-
vation of 7 with DCC, which gave the known cyclic uridine
50-trimetaphosphate (8), followed by condensation with 1.
This route proved to be the most robust and afforded the
best impurity profile for purification. Alternately, 3 could be
activated with CDI to give the corresponding imidazolide
(6), which was condensed with 3 to give 9.U P 4U could also
be produced by the reaction of phosphorimidazolide 2 with
pyrophosphate.
Diuridine 50-pentaphosphate (UP5U, 10), diuridine 50-hexa-
phosphate (UP6U, 11) and diuridine 50-heptaphosphate
(UP7U, 12) were generated as minor byproducts. All three
of the described routes give rise to these impurities, in part
because of the ability of the tetraphosphate linkage to un-
dergo disproportionation. That is, conditions which enable
phosphate linkage formation also enable the linkage to
break apart generating mononucleotides which can then
react in an unintended manner. Impurities in UTP (7) are
most responsible for appearance of these impurities, as the
DCC-mediated route is the most facile pathway. Com-
pound 10 was generated by the coupling of 8 with 3, which
was present as a small impurity in 7. Compound 11 arose
from the condensation of 8 with 7, either as a result of a
small amount of hydrolysis of 8 back to UTP (7) in the
reaction mixture or by incomplete conversion to the cyclic
meta-triphosphate intermediate (8). Compound 12 was
likely generated from the reaction between 8 and uridine
50-tetraphosphate (UP4), which is present as a minor impurity
in 7.
Unsymmetrical dinucleotides are prepared in a manner
analogous to the procedures described for the preparation
of symmetrical dinucleotides. For the cases of dinucleo-
tides with diphosphate or triphosphate linkages, the order
Figure 1. General structure of dinucleoside polyphosphates.
Figure 2. General synthetic scheme for dinucleoside di- and triphosphates using a monophosphate as the starting nucleotide.
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reaction yield or ease of synthesis. However, in the case of
the tetraphosphates, there was a significant difference in the
outcome of the reaction owing to the ease or difficulty in
forming the cyclic meta-triphosphate and to the solubility
properties of various monophosphates. This was especially
evident in the reactions of cytidine and guanosine nucleo-
tides, probably owing to the zwitterionic character of these
compounds. The complexity of the unsymmetrical reactions
is caused by the same factors that create the di-, tri-, tetra-,
penta-, hexa-, and heptaphosphate impurities present in the
symmetrical reactions. Again considering the tetraphosphate
synthesis, the symmetrical reaction scheme will generate a
distribution of these six dinucleotides. However, the
unsymmetrical scheme will generate the same set of six
dinucleotides with not only the expected set of nucleoside
moieties, but all of the possible combinations thereof. These
reaction mixtures often gave rise to impurity profiles with
18 peaks observed by HPLC. These impurities were minor
components of the reaction, but the broad range of retention
times that these various impurities represented created a
challenge for purification of the desired material.
Figure 3. General methods for synthesis of dinucleoside tetraphosphates.
Table 1. Dinucleoside diphosphates, n = 0 (see Figure 1) EC50 (2M).
Base 1 Base 2 P2Y1 P2Y2 P2Y4 P2Y6
13 Adenosine Adenosine 4.25 NR NR NR
14 Adenosine Uridine 2.85 23.4 910 NR
15 Adenosine Cytidine 2.11 6.9 SR 18.8
16 Adenosine Guanosine 26.5 1.3 1.5 9.14
17 Adenosine 20-Deoxyguanosine 24.6 SR NR 910
4 Uridine Uridine NR NR NR 33.0
18 Uridine Guanosine SR 2.1 4.64 7.54
19 Uridine 20-Deoxyuridine NR NR NR NR
20 Uridine 20-Deoxyguanosine 910 29.0 910 910
21 Cytidine Cytidine NR NR NR NR
22 Inosine Inosine SR 4.8 5.06 910
23 4-Thiouridine 4-Thiouridine 910 29.1 33.9 25.2
24 20-Deoxycytidine 20-Deoxycytidine NR NR NR SR
SR = slight response at 100 2M, NR = no response, NT = not tested.
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acting upon numerous P2Y and P2X receptors in various
tissues throughout the body. An examination of the require-
ments, or preferences, of the nucleoside components of these
dinucleoside polyphosphates in terms of P2Y receptor ac-
tivity has not been undertaken in a systematic fashion. To
accomplish this, reproducible and dynamic synthetic meth-
ods were developed to make a relatively complete and rep-
resentative set of dinucleotides using mostly naturally
occurring nucleoside/tide starting materials. Synthetic meth-
ods existed for compounds containing adenosine and
guanosine but few methods were applicable beyond these
purine examples.
The results show that the phosphate chain length was an
important determinant for specificity among the receptor
subtypes. We have shown that symmetrical dinucleoside
tetraphosphates have similar activities and specificities to
the analogous nucleoside triphosphate. UTP and ATP are
natural substrates for the P2Y2 receptor and dinucleoside
tetraphosphates containing either uridine or adenosine are
highly active as agonists of the same receptor. This same
trend is followed by symmetrical dinucleoside triphos-
phates which are structural mimics of the analogous
nucleoside diphosphates; that is, ADP is a potent agonist
for the human P2Y1 receptor and adenosine containing
dinucleoside triphosphates are highly active agonists at this
receptor. Similarly, UDP is a potent agonist at the P2Y6
receptor as well as uridine containing dinucleoside triphos-
phates. The identity of the nucleobases in these dinucleo-
tides was not responsible for the presence or lack of
activity except for the necessity of adenosine for P2Y1
agonism and uridine for P2Y6 agonism. None of the
Table 2. Dinucleoside triphosphates, n = 1 (see Figure 1) EC50 (2M).
Base 1 Base 2 P2Y1 P2Y2 P2Y4 P2Y6
ADP 0.014 NR NR NR
UDP NR 4.2 9.5 0.5
25 Adenosine Adenosine 0.011 28.5 NR NR
26 Adenosine Uridine 0.039 2.00 910 0.17
27 Adenosine Cytidine 0.085 6.00 NR 910
28 Adenosine Guanosine 0.12 0.23 0.52 1.53
29 Adenosine Inosine 0.11 1.20 2.55 1.06
30 Uridine Uridine NR 13.0 SR 0.92
31 Uridine Cytidine SR 2.00 16.7 0.52
32 Uridine Guanosine NR SR NR 0.38
33 Uridine Inosine NR 4.50 SR 1.31
34 Uridine 2_-Deoxyguanosine NR 0.47 1.98 0.28
35 Cytidine Inosine 910 910 SR NT
36 Cytidine 2_-Deoxyuridine 17.0 3.1 40.0 0.81
37 Inosine Guanosine SR 910 6.41 910
38 Guanosine Guanosine NR NR NR NR
SR = slight response at 100 2M, NR = no response, NT = not tested.
Table 3. Dinucleoside tetraphosphates, n = 2 (see Figure 1) EC50 (2M).
Base 1 Base 2 P2Y1 P2Y2 P2Y4 P2Y6
ATP 0.65 0.015 NR NR
UTP NR 0.015 0.07 1.47
39 Adenosine Adenosine 0.32 0.054 NR SR
40 Adenosine Uridine 4.75 0.35 1.45 SR
41 Adenosine Cytidine 0.75 0.15 NR SR
42 Adenosine Inosine 0.55 0.17 NR NR
43 Uridine Uridine NR 0.06 0.20 24.8
44 Uridine Cytine SR 0.46 0.85 12.1
45 Uridine Inosine NR 0.52 0.28 910
46 Uridine Thymidine NR 0.18 0.35 NR
47 Uridine 4-Thiouridine NR 0.04 0.17 190.0
48 Uridine 2_-Deoxyinosine NR 0.23 0.47 910
49 Uridine 2_-Deoxyguanosine SR 0.06 0.14 1.68
50 Uridine Aracytidine 6.13 0.59 0.22 3.32
51 Uridine 2-Deoxycytidine NR 0.27 1.22 16.0
52 Uridine 2_Deoxyadenosine 3.49 0.05 0.07 4.20
53 Uridine Xanthosine NR 0.11 0.24 5.52
54 Cytidine Cytidine SR SR NR SR
55 Cytidine 4-Thiouridine SR 0.036 0.11 5.22
56 4-Thiouridine 4-Thiouridine SR 0.082 0.09 6.82
SR = slight response at 100 2M, NR = no response, NT = not tested.
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at any of the receptor subtypes tested.
Mixed base dinucleotides represent a unique opportunity
to manipulate selectivity and activity on various receptor
subtypes. As previously stated, dinucleoside tetraphos-
phates mimic the analogous mononucleoside triphosphates.
As cytidine nucleotides have minimal activity on all
receptors, one may expect a cytidine containing dinucleo-
tide to have poor activity. Consistent with this hypothesis,
no activity on any receptor was noted when cytidine or
deoxycytidine was at both ends of a symmetrical dinucle-
otide. However, the activity profile of cytidine-containing
mixed-base dinucleotides (or dinucleotides containing other
less active mononucleotides) is shown to reside with the
more active nucleobase. AP4C has good activity primarily at
the P2Y1 receptor whereas UP4C has activity primarily at
the P2Y2 receptor. Guanosine-containing dinucleotides
follow the same trend as the cytidine-containing dinucleo-
tides. The symmetrical guanosine dinucleotides exhibit no
agonist activity on any of the receptors tested (GP2Ga n d
GP4G data not shown) but as unsymmetrical dinucleotides,
some of these guanosine-containing compounds show good
activity (UP3Go nP 2 Y 6 and UP4dG on P2Y2). AP4Uh a s ,a s
one may expect, activity at P2Y1,P 2 Y 2, and P2Y4 as it
contains both adenosine and uridine bases.
One of the advantages dinucleotides have over mono-
nucleotides is an increase in both chemical and metabolic
stability. Chemically, these dinucleotides are stable to
prolonged dry storage at room temperature. Mononucleo-
tides, and particularly triphosphates, must be stored at or
below 0 -C to maintain purity at a high level. High pH
(greater than 9) must be maintained for these mononucleo-
tides to exist as relatively pure solutions. At neutral pH or
lower, these mononucleotides slowly degrade into the
constituent lower nucleotides eventually generating the free
nucleoside. Dinucleotides need no such gentle treatment to
maintain a high degree of purity in solution.
Metabolic instability of mononucleotides is well known
[30], and is an important part of their transient endogenous
activity. However, this instability of mononucleotides
render them unattractive as therapeutic agents. Dinucleo-
tides, on the other hand, have a much higher degree of
metabolic stability [31]. Within our series of dinucleotides,
there is a fairly wide range of stability on bronchial epi-
thelial cells. As shown in Figure 4, a variety of dinu-
cleotides were tested to determine their relative stabilities
compared to the mononucleotide, uridine triphosphate
(UTP). Diadenosine tetraphosphate is the least stable of
the dinucleosides tested. The most hydrolysis-resistant
compounds are the ones which contain a cytosine base.
Therefore, selection of a dinucleoside therapeutic should
be chosen based on a combination of receptor activity, re-
ceptor selectivity, and the metabolic stability in the rele-
vant system.
Conclusion
Dinucleoside polyphosphates represent a metabolically and
chemically more stable series of nucleotide analogs. Their
intrinsic activities on the various purinergic receptors (P2Y1,
P2Y2,P 2 Y 4,P 2 Y 6) are as full agonists with a predictive
specificity. Adenosine containing dinucleotides have at least
minimal activity on P2Y1 while uridine containing dinu-
cleotides have at least minimal activity on P2Y2 and P2Y6.
The length of the linking phosphate chain determines a
different specificity; diphosphates are most accurately
mimicked by dinucleoside triphosphates and triphosphates
most resemble dinucleoside tetraphosphates. By making an
appropriate choice of phosphate length and nucleobase
composition, we have been able to find compounds with
necessary stability, efficacy, and specificity to enter into
clinical efficacy testing in chronic diseases such as cystic
fibrosis and dry eye.
Experimental
Reagents
All starting materials and the dinucleotides AP2A, AP3A,
and GP3G were obtained from Sigma (St. Louis, MO)
unless otherwise stated. The purity of all nucleotide ago-
nists was established by either reverse phase or anion
exchange HPLC (95%Y99% purity). Fluo-3-AM was ob-
tained from Molecular Probes (Eugene, OR). Dulbecco’s
modified Eagle’s medium (DMEM), fetal bovine serum G-
418, and other cell culture reagents were obtained from the
Tissue Culture Facility at the University of North Carolina,
or from Gibco-BRL Life Technologies (Rockville, MD).
1321N1 human astrocytoma cells stably expressing the
P2Y1,P 2 Y 2, P2Y4,o rP 2 Y 6 receptors, and wild-type
1321N1 cell were obtained from the University of North
Carolina at Chapel Hill.
Intracellular calcium mobilization
1321N1 human astrocytoma cells stably expressing the
human P2Y1,P 2 Y 2, P2Y4, and P2Y6 receptors were grown
in DMEM containing 4.5 g/l glucose, 5% fetal bovine
serum and 600 2g/ml G-418. For intracellular Ca
2+
measurements, cells were seeded in 96-well black wall/
clear bottom culture plates (#3904 Corning Inc., Corning,
NY), at a density of 35,000 cells/well and assays conducted
2 days later when the cells had reached confluence.
Figure 4. Structure of diuridine polyphosphates.
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culture plates was aspirated and replaced with 2.5 2M
Fluo-3-AM in a final volume of 50 2l and incubated for
one hour at 25 -C. Then, the dye was replaced with assay
buffer (10 mM KCl, 118 mM NaCl, 2.5 mM CaCl2,1m M
MgCl2, 10 mM glucose, and 20 mM HEPES, pH 7.4),
using a Columbus Plate Washer (Tecan Inc., Research
Triangle Park, NC). Intracellular Ca
2+ levels in response to
P2Y receptor agonists were monitored as changes in
fluorescence intensity using a Fluorescent Light Imaging
Plate Reader (FLIPR) from Molecular Devices (Sunnyvale,
CA). Average fluorescence units (AFU) corresponding to
peak height were captured on disk and exported for further
analysis. Changes in fluorescence data corresponding to
concentrations of intracellular Ca
2+ were normalized to
the response of the cognate agonists (2MeSADP for P2Y1
receptor, ATP for P2Y2 receptor, UTP for P2Y4 receptor,
and UDP for P2Y6 receptor).
Agonist potencies were calculated using a four-param-
eter logistic equation and the GraphPad software package
(San Diego, CA). EC50 values represent the concentration
of agonist at which 50% of the maximal effect is achieved.
Three experiments using triplicate assays were conducted
on separate days for each P2Y receptor subtype.
Airway surface metabolism
Well-differentiated cultures from passage 1 (P1) human
airway epithelial cells were grown as previously described
[31]. In brief, nasal epithelial cells were harvested from
turbinates. Primary cells were isolated by protein digestion
and plated on a collagen-coated tissue culture dish (5Y10
days) in LHC9 medium containing: 25 ng/ml EGF, 50 nM
retinoic acid, 40 2g/ml gentamicin, 0.5 mg/ml bovine
serum albumin, 0.8% bovine pituitary extract, 50 U/ml
penicillin, 50 2g/2l streptomycin and 0.125 mg/ml ampho-
tericin) termed bronchial epithelial growth medium
(BEGM). The cells were trypsinized and subpassaged on
porous Transwell Col filters (diameters: well, 24 mm; pore,
0.45 2M) in airYliquid interface (ALI) medium. ALI is
similar to BEGM, except for a 50:50 mixture of LHC Basal
and DMEM-H as the base, amphotericin and gentamicin
are omitted, and EGF concentration is reduced to 0.5 ng/
ml. After 4 weeks, the cultures were composed of colum-
nar ciliated cells (990%) and secretory cells covering a
layer of basal-like cells. Enzyme assays were conducted on
cultures of transepithelial electrical resistance Q 300 4/cm
2.
Extracellular lactate dehydrogenase, employed as a test of
cellular integrity, was tested 1 day before the nucleotide
assays.
On the day of the experiments, the cell surfaces were









2+, 5.2 glucose and 25 HEPES (pH 7.4) and then pre-
incubated in KRB (0.35 ml mucosal/2 ml serosal) for 30
min at 37 -C (5% CO2/95% O2). The enzyme reaction was
initiated by the addition of 0.1 mM mono- or dinucleotide,
dissolved in 35 2l KRB, to the mucosal bath and stopped by
transferring 30 2l aliquots to tubes containing 0.3 ml ice-cold
water. The samples were boiled 5 min, filtered, and analyzed by
reversed-phase paired-ion HPLC (Figure 5).
The HPLC system consisted of a Dinamax C-18 column and
a mobile phase developed with buffer A (10 mM KH2PO4 and
8 mM TBASH, pH 5.3) from 0 to 15 min, buffer B (100 mM
KH2PO4, 8 mM TBASH and 10% MeOH, pH 5.3) from 15
to 35Y60 min and buffer A from 35Y60 to 45Y75 min.
Absorbance was monitored at 254 nm with an on-line Model
490 multi-wavelength detector (Shimadzu Sci. Instr. Inc.,
Maryland, USA). Degradation rates were calculated from the
decrease in the amount of substrate monitored by HPLC and
presented as nmol/min cm
2 of surface area. Values were
expressed as means T standard error of the mean (SEM).
Unpaired and paired Student’s t-tests were used to assess the
significance of differences between means. All linear regres-
sions, curve fits and data transformations were performed
with PC computer programs Origin and Sigma plot.
Standard preparation of dinucleoside diphosphates
UP2U (4)U r i d i n e5 0-monophosphate, monotributylam-
monium salt (1.45 g, 2.85 mmol) was dissolved in dry DMF
(12 ml) and CDI (0.346 g, 2.13 mmol) added in a single
portion. The reaction mixture was heated at 50 -C for 24 h,
after which the solvent was removed. This residue was
dissolved in a minimal volume of water and purified by
preparative ion exchange HPLC (Hamilton PRP-X100
column, 250   50 mm, 10 2m, with a linear gradient from
water to 90% 1 M NH4HCO3/10% acetonitrile). The
fractions containing the product were pooled and the water
Figure 5. Time-course of the metabolism of various nucleotides by
human normal bronchial cells. The cells were grown to confluence on an
airYliquid interface and differentiated into a ciliated cell sheath over 4
weeks. The cells were pre-incubated 30 min at 37-C in Krebs buffer (0.35
ml apical/2 ml basolateral; pH 7.4). The assays were started with 0.1 mM
nucleotide added to the apical buffer. Aliquots of 30 2l were transferred to
0.3 ml ice-cold water and boiled during 5 min. Their content in nucleotides
was analyzed by HPLC. Data are expressed as percent of initial peak
(SEM G 10%; N =4 Y8).
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nium salt (0.596 g, 63% yield).
Standard preparation of dinucleoside triphosphates
AP3U (26) Uridine 50-diphosphate, bistributylammonium
salt (68.2 mg, 0.088 mmol) and adenosine 50-phosphomor-
pholidate (100 mg, 0.141 mmol) were dissolved in 1 ml of
anhydrous pyridine.
1H tetrazole (19.7 mg, 0.282 mmol)
was added to the solution and stirred at 50 -C overnight.
The reaction was quenched with triethylammonium bicar-
bonate (0.5 M, 1 ml) then stirred for 45 min at room
temperature. The aqueous solution was extracted with an
equal volume of ethyl acetate to remove excess organics
then evaporated to a viscous oil. This residue was dissolved
in a minimal volume of water and purified by preparative
ion exchange HPLC (Hamilton PRP-X100 column,
250   50 mm, 10 2m, with a linear gradient from water
to 90% 1 M NH4HCO3/10% acetonitrile). The fractions
containing the product were pooled and the water removed
by lyophilization to give the product as the triammonium
salt (15.07 mg, 21.6% yield).
Standard preparation of dinucleoside tetraphosphates
AP4U (40) Adenosine 50-triphosphate bistributylammo-
nium salt (2.0 g, 2.28 mmol) was dissolved in dry DMF
(15 ml) and DCC (0.517 g, 2.51 mmol) added over 30 s.
The solution was stirred at room temperature for 45 min,
during which time it became rather heterogeneous.
31P
NMR indicated almost complete conversion to the cyclical
trimetaphosphate, and uridine 50-monophosphate, mono-
tributylammonium salt (1.28 g, 2.51 mmol) was added as a
solid. The reaction mixture was stirred at 30Y35 -C for 60 h,
by which time HPLC indicated that the desired product
constituted about 40% of the total nucleotide content. The
precipitated dicyclohexylurea was filtered, and the solvent
was evaporated. This residue was dissolved in a minimal
volume of water and purified by preparative ion exchange
HPLC (Hamilton PRP-X100 column, 250 50 mm, 10 2m,
with a linear gradient from water to 90% 1 M NH4HCO3/
10% acetonitrile). The fractions containing the product were
pooled and the water removed by lyophilization to give
AP4UI 4NH4 (560 mg, 28% yield).
Analytical data
Common naming format is used below instead of IUPAC
nomenclature (AP4A = diadenosine tetraphosphate).
UP2U (4)
1HN M R( D 2O): % 7.73 (d, H6), 5.78Y5.74
(m, H5, H10), 4.17Y3.98 (m, H20,H 3 0,H 4 0,H 5 0);
31PN M R
(D2O): % j10.10 (s, P1, P2)
AP2U (14)
1HN M R( D 2O): % 8.23 (s, A-H8), 7.97
(s, A-H2), 7.42 (d, U-H6), 5.88 (m, U-H10), 5.6 (m, A-H10),
5.4 (m, U-H5), 4.4Y3.9 (m, A&U-H20,H 3 0,H 4 0,H 5 0);
31P
NMR (D2O): % j10.14 (m, P1, P2)
AP2C (15)
1HN M R( D 2O): % 8.27(s, A-H8), 8.04 (s,
A-H2) 7.59 (d, C-H6), 5.82 (d, C-H5), 5.71Y5.47 (m, AC-
H10), 4.41 (m, A&C-H20,H 3 0,H 4 0,H 5 0);
31PN M R( D 2O):
% j9.97 (m, P1, P2)
AP2G (16)
1HN M R( D 2O): % 8.05 (s, A-H8), 7.9 (s, A-H2),
7.7 (s, G-H8), 5.78 (d, A-H10), 5.55 (d, G-H10), 4.45Y3.98
(m, A&G-H20,H 3 0,H 4 0,H 05);
31PN M R( D 2O): % j9.95
(m, P1, P2)
AP2dG (17)
1H NMR (D2O): % 8.13 (s, A-H8), 7.92 (s,
A-H2), 7.77 (s, G-H8), 5.82 (d, A-H10), 5.61 (d, dG-H10),
4.47Y4.28 (m, G&A-H20,H 3 0), 4.2Y4.01 (m, G&A-40,5 0);
31PN M R( D 2O): % j10.07 (d, P1, P2)
UP2G (18)
1H NMR (D2O): % 7.85 (s, G-H8), 7.58 (d,
U-H6), 5.7Y5.58 (m, G&U-H10,U - H 5 )4 . 3 Y4.05 (m,
G&U-20,3 0,4 0,5 0);
31PN M R( D 2O): % j10.13 (m, P1,
P2)
UP2dU (19)
1H NMR (D2O): % 7.75Y7.71 (m, U&dU-H6),
6.14 (t, dU-H10), 5.76Y5.71 (m, U-H10, U&dU-H5),
4.64Y4.07 (m, U-20,U & d U ,3 0,4 0,5 0), 2.18 (dU-20);
31P
NMR (D2O): % j10.15 (m1, P1, P2)
UP2dG (20)
1HN M R( D 2O): % 7.8 (s, G-H8), 7.56 (d,
U-H6), 5.8Y5.75 (m, U-H5), 5.77Y5.6 (m, U&dG-H10),
4.3Y3.93 (m, U-H20, U&dG-H30,H 4 0,H 5 0), 2.6Y2.2 (m,
dG-H20);
31PN M R( D 2O): % j10.16 (d, P1, P2)
CP2C (21)
1H NMR (D2O): % 7.96 (d, H6), 6.1 (d, H5),
5.7 (d, H10), 4.13Y4.00 (m, H20,H 3 0,H 4 0,H 5 0);
31P NMR
(D2O): % j11.38 (m, P1, P2)
IP2I (22)
1HN M R( D 2O): % 7.75 (d, H6), 6.16 (m, H10),
5.88 (d, H5), 4.39 (s, H30), 4.02 (m, H50), 2.26Y2.1(m, H20);
31P NMR (D2O): % j10.14 (m, P1, P2)
4-thioUP24-thioU (23)
1HN M R( D 2O): % 7.6 (d, H6),
6.4 (d, H5), 5.8 (s, H3), 4.7Y4.02 (m, H20,H 3 0,H 4 0,H 5 0);
31PN M R( D 2O): % j11.30 (m, P1, P2)
dCP2dC (24)
1HN M R( D 2O): % 7.73 (d, H6), 6.14 (d,
H10), 5.88 (d, H5), 4.3Y3.96 (m, H30,H 4 0,H 5 0), 2.27Y2.06
(m, H20);
31P NMR (D2O): % j10.11 (m, P1, P2)
AP3U (26)
1HN M R( D 2O): %.3 (s, A-H8), 8.02 (s, A-
H2), 7.62 (d, U-H6), 5.93Y5.52 (m, U-H5, UA-H10), 4.63Y4.07
(m, U&A-20,3 0,4 0,5 0);
31P NMR (D2O): % j10.20,
10.30 (dd, P1, P3), j21.85 (t, P2)
AP3C (27)
1HN M R( D 2O): % 8.2 (s, A-H8), 8.02 (s,
A-H2) 7.6 (d, C-H6), 5.8 (d, C-H5), 5.7Y5.45 (m, A&C-
H10), 4.4 (m, A&C-H20, H3, H40,H 5 0);
31P NMR (D2O): %
j10.02, j10.21 (dd, P1, P3),j21.6 (t, P2)
AP3G (28)
1HN M R( D 2O): % 8.2 (s, A-H8), 8.00 (s,
A-H2), 7.9 (s, G-H8), 5.8 (d, A-H10), 5.6 (d, G-H10),
4.8Y4.02 (m, G&A-H20,H 3 0,H 4 0,H 5 0);
31PN M R( D 2O):
% j11.28, j10.37 (dd, P1, P3), j22.94 (t, P2)
AP3I (29)
1HN M R( D 2O): % 8.17 (s, A-H8), 8.16 (s,
I-H8), 8.01 (s, A-H2), 7.98 (s, I-H2), 5.89Y5.82 (m, A&I-H10),
4.55Y4.11 (m, A&I-H20,H 3 0,H 4 0,H 5 0);
31PN M R( D 2O):
% j10.28, j10.37 (dd, P1, P3), j21.94 (t, P2)
UP3U (30)
1HN M R( D 2O): % 7.82 (d, H6), 5.85Y5.80
(m, H5, H10), 4.25 (m, H20,H 3 0), 4.10 (m, H40,H 5 0);
31P
NMR (D2O): % j10.45 (d, P1, P3), j22.20 (t, P2)
UP3C (31)
1H NMR (D2O): % 7.83Y7.78 (m, U&C-H6),
5.97 (d, C-H5), 5.83Y5.78 (m, U-H5, H10, C-H10), 4.3 (m,
C&U-20,3 0,4 0,5 0);
31P NMR (D2O): % j10.28, j10.37 (dd,
P1, P3), j21.94 (t, P2)
UP3G (32)
1HN M R( D 2O): % 7.93 (s, G-H8), 7.70 (d,
U-H6), 5.7Y5.64 (m, G&U-H10), 5.61 (d, U-H5), 4.3Y4.01
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31P NMR (D2O): % j10.26, j10.34
(dd, P1, P3), j21.87 (t, P2)
UP3I (33)
1H NMR (D2O): % 8.3; (s, I-H8), 8.02 (s, I-
H2), 7.77 (d, U-H6), 5.95 (d, U-H5), 5.8Y5.6 (m, U&I-
H10),4.41Y3.93 (m, U&I-20,3 0,4 0,5 0);
31P NMR (D2O): %
j10.31, j10.9 (dd, P1, P3), j21.81 (s, P2)
UP3dG (34)
1H NMR (D2O): % 7.8 (s, G-H8), 7.6 (d,
U-H6), 5.8 (d, U-H5), 5.77Y5.6 (m, U&dG-H10), 4.3Y3.93
(m, U-H20,U & d G - H 3 0,H 4 0,H 5 0), 2.6Y2.2 (m, dG-H20);
31P
NMR (D2O): % j10.20, j10.4 (dd, P1, P3), j21.9 (t, P2)
CP3I (35)
1H NMR (D2O): % 8.3 (s, I-H8), 8.02 (s, I-H2),
7.8 (d, C-H6), 5.95 (d, C-H5), 5.8Y5.6 (m, C&I-H10),
4.41Y3.93 (m, C&I-20,3 0,4 0,5 0);
31P NMR (D2O): %
j10.02, j10.3 (dd, P1, P3), j22.43 (t, P2)
CP3dU (36)
1HN M R( D 2O): % 7.6 (d, U-H6), 7.45 (d,
C-H6), 6.14 (t, dU-H10), 5.9Y5.57 (m, C-H10, dU&C-H5),
4.4Y3.9 (m, C-H20,C & d U - H 3 0,H 4 0,H 5 0), 2.18 (dU-20);
31P NMR (D2O): % j10.05, j10.4 (dd, P1, P3), j21.95
(t, P2)
IP3G (37)
1H NMR (D2O): % 8.1(s, I-H8), 8.00 (s, I-H2),
7.8 (s, G-H8), 5.8 (d, I-H10), 5.6 (d, G-H10), 4.8Y4.02
(m, G&I-H20,H 3 0,H 4 0,H 5 0);
31PN M R( D 2O): % j10.2,
j10.6 (dd, P1, P3), j21.88 (t, P2)
AP4A (39)
1HN M R( D 2O): % 8.16 (s, H8), 7.9 (s, H2),
5.83 (d, H10), 4.54Y4.05 (m, H20,H 3 0,H 4 0,H 5 0);
31P NMR
(D2O): % j10.60 (m, P1, P4), j22.28 (m, P2, P3)
AP4U (40)
1H NMR (D2O): % 8.36 (s, A-H8), 8.07 (s,
A-H2), 7.68 (d, U-H6), 5.94Y5.66 (m, U-H5, U&A-H10),
4.41Y4.06 (m, U&A-H20,H 3 0,H 4 0,H 5 0);
31PN M R( D 2O):
% j10.73 (m, P1, P4), j22.34 (m, P2, P3)
AP4C (41)
1H NMR (D2O): % 8.34 (s, A-H8), 8.05 (s,
A-H2), 7.63 (d, C-H6), 5.85 (d, A-H10), 5.78Y5.73 (m, C-H5,
H10), 4.42Y4.07 (m, C&A-H20,H 3 0,H 4 0,H 5 0);
31PN M R
(D2O): % j10.23 (m, P1, P4), j21.99 (m, P2, P3)
AP4I (42)
1HN M R( D 2O): % 8.28 (s, A-H8), 8.19 (s,
I-H8), 8.05 (s, A-H2), 7.95 (s, I-H2), 5.89Y5.82 (m, A&I-H10),
4.65Y4.11 (m, A&I-H20,H 3 0,H 4 0,H 5 0);
31P NMR (D2O): %
j10.07 (m, P1, P4), j22.00 (m, P2, P3)
UP4U (43)
1HN M R( D 2O): % 7.8 (1H, d, H6), 5.85 (d,
H5), 5.83 (d, H10), 4.26 (m, H20,H 3 0), 4.12 (m, H40,H 5 0);
31P
NMR (D2O): % j10.75 (m, P1, P4), j22.32 (m1, P2, P3)
UP4C (44)
1HN M R( D 2O): % 7.8Y7.73 (m, C&U-H6),
5.94 (d, C-H5), 5.78Y5.75 (m, U-H5, U&C-H10), 4.15Y4.02
(m, U&C-H210,H 3 0,H 4 0,H 5 0);
31P NMR (D2O): % j10.84
(m, P1, P4), j22.65 (m, P2, P3)
UP4I (45)
1HN M R( D 2O): % 8.43 (s, I-H8), 8.08 (s, I-H2),
7.75 (d, U-H6), 5.98 (d, I-H10), 5.79Y5.73 (m, U-5, 10),
4.3Y4.0 (m, U&I-20,3 0,4 0,5 0);
31PN M R( D 2O): % j10.86
(m, P1, P4), j22.61 (m, P2, P3)
UP4T (46)
1H NMR (D2O): % 7.80 (d, U-H6), 7.59 (s,
T-H6), 6.17 (t, T-H10), 5.82Y5.79 (m, U-H5, U-H10),
4.30Y4.00 (m, U-H20, U&T-H30,H 4 0,H 5 0), 2.19 (m, T-H20),
1.76 (s, T-5CH3);
31P NMR (D2O): % j10.34 (m, P1, P4),
j22.10 (m, P2, P3)
UP44-thioU (47)
1HN M R( D 2O): % 7.71 (d, U-H6), 7.56
(d, thioU-H6), 6.41 (d, thioU-H5), 5.74Y5.70 (m, U-H10,
H5, thioU-H10), 4.64Y4.60 (m, thioU&U-H20,H 3 0,H 4 0,
H50);
31P NMR (D2O): % j10.22 (m, P1, P4), j21.77
(m, P2, P3)
UP4dI (48)
1H NMR (D2O): % 8.27 (s, dI-H8), 8.03 (s,
dI-H2), 7.75 (d, U-H6), 6.32 (m, dI-H10), 5.76 (m, U-H5,
H10) 4.22Y4.06 (m, U-H20, U&dI-H30,H 4 0,H 5 0), 2.67Y2.42
(m, dI-H20);
31PN M R( D 2O): % j10.22 (m, P1, P4), j22.17(m,
P2, P3)
UP4dG (49)
1H NMR (D2O): % 7.9 (s, dG-H8), 7.70 (d,
U-H6), 6.11(t, U-5), 5.79Y5.70 (m, U&dG-H10), 4.25Y4.02
(m, U-H20, U&dG-H30,H 4 0,H 5 0) 2.6Y2.2 (m, dG-H20);
31P
NMR (D2O): % j10.72 (m, P1, P4), j22.35 (m, P2, P3)
UP4araC (50)
1H NMR (D2O): % 7.81Y7.76 (m, U&C-
H6), 6.15Y6.0 (m, C-H10), 5.85Y5.78 (m, U-H10, U&C-H5),
4.3Y4.0 (m, U&C-H20,H 3 0,H 4 0,H 5 0);
31PN M R( D 2O): %
j10.79 (m, P1, P4), j22.52 (m, P2, P3)
UP4dC (51)
1H NMR (D2O): % 7.8 (m, dC-H6, U-H6),
6.1 (t, dC-H10), 5.93 (d, dC-H10), 5.93 (d, dC-H5), 5.76 (m,
U-H10,H 5 ) ,4 . 2 Y4.0 (m, U-20, dC&U-H30,H 4 0,H 5 0),
2.3Y2.0 (m, dC-H20);
31P NMR (D2O): % j10.81 (m, P1, P4),
j22.62 (m, P2, P3)
UP4dA (52)
1HN M R( D 2O): % 8.31(d, dA-H8), 8.06 (d,
dA-H2), 7.72 (d, U-H6), 6.33 (d, dA-H10), 5.74Y5.65 (M,
U-H10, H5), 4.20Y4.02 (m, U-H20, dA&U-H30,H 4 0,H 5 0),
2.4Y2.6 (m, dA-H20);
31P NMR (D2O): % j10.81 (m, P1,
P4), j22.6 (m, P2, P3)
UP4X (53)
1H NMR (D2O): % 7.88 (s, X-H8), 7.70 (d,
U-H6), 5.76Y5.70 (m, U-H5, H10,X - H 1 0), 4.49Y3.92 (m,
X&U-H20,H 3 0,H 4 0,H 5 0);
31P NMR (D2O): % j10.73
(m, P1, P4), j22.4 (m, P2, P3)
CP4C (54)
1H NMR (D2O): % 7.77 (d, C-H6), 5.96 (D, C-
H5), 5.81 (d, C-H10), 4.21Y4.09 (m, C-H10,H 2 0,H 3 0,H 4 0,
H50);
31P NMR (D2O): % j10.81 (m, P1, P4), j22.29 (m,
P2, P3)
CP44-thioU (55)
1HN M R( D 2O): % 7.79 (d, C-H6),
7.66 (d, U-H6), 6.48 (d, U-H5), 5.98 (d, C-H10), 5.81 (d,
C-H5), 5.76 (d, U-H10), 4.25Y4.0 (m, U&C-H20,H 3 0,H 4 0,
H50);
31P NMR (D2O): % j11.40 (m, P1, P4), j22.96 (m,
P2, P3)
4-thioUP44-thioU (56)
1HN M R( D 2O): % 7.67 (d, H6),
6.48 (d, H5), 5.77 (s, H10), 4.30Y4.05 (m, H20,H 3 0,H 4 0,
H50);
31P NMR (D2O): % j11.41 (m, P1, P4), j22.79 (m,
P2, P3)
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